Supernus Pharmaceuticals Inc. reported total revenues of $192.1 million for the third quarter of 2025, a 9% increase compared to the same period in 2024. Combined revenues from the company's four growth products rose 52% to $149.2 million, driven by higher net sales of Qelbree and GOCOVRI, as well as the addition of sales from ZURZUVAE and ONAPGO. Net product sales for Qelbree reached $81.4 million, an increase of 31% from $62.4 million in the third quarter of 2024, while GOCOVRI sales were $40.8 million, up 15% from $35.6 million. The company completed the acquisition of Sage Therapeutics on July 31, 2025. Operating losses for the quarter were $60.2 million, impacted by higher selling, general and administrative expenses, including $70.0 million in acquisition-related costs. Adjusted operating earnings (non-GAAP) for the quarter were $41.9 million, compared to $67.7 million in the same period the previous year. Cash, cash equivalents, and current marketable securities totaled approximately $281.2 million as of September 30, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Supernus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568656-en) on November 04, 2025, and is solely responsible for the information contained therein.
Comments